Additionally, a phase 2 clinical trial (NCT05907954) is investigating darovasertib (IDE196), a protein kinase C (PKC) inhibitor, as a neoadjuvant/adjuvant treatment prior to local therapy for patients with tumours harbouring GNA11 or GNAQ mutations [36,37]. Here, PRRT2 is linked to neoplasm.